Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751420 | 1.00 | AAK1 (0.47) | AAK1KDM4AEPAS1NPC1RECQL | |
| SCHEMBL506329 | 0.89 | AAK1 (0.50) | AAK1KDM4AFPR3FPR2 | |
| SCHEMBL30101829 | 0.87 | AAK1 (0.46) | AAK1KDM4ANPC1RECQLRAB9A | |
| SCHEMBL31142972 | 0.86 | AAK1 (0.47) | AAK1KDM4ANPC1RECQLRAB9A | |
| SCHEMBL18719605 | 0.86 | KDM4A (0.45) | AAK1KDM4ANPC1RECQLRAB9A | |
| SCHEMBL8011978 | 0.86 | AAK1 (0.47) | AAK1KDM4ANPC1RECQLRAB9A | |
| SCHEMBL6559693 | 0.85 | TSHR (0.43) | SMN1; SMN2GAA | |
| SCHEMBL27804602 | 0.85 | AAK1 (0.47) | AAK1KDM4ANPC1RECQLRAB9A | |
| SCHEMBL24885830 | 0.84 | NQO2 (0.49) | KDM4ANPC1RAB9AGAAJAK2 | |
| SCHEMBL20869031 | 0.84 | EGFR (0.44) | AAK1KDM4ANPC1RECQLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| CN-119654324-A | Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same | 株式会社次代生物科学 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024030000-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030000-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| WO-2023002011-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-01-26 | — | — | WO | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2976340-B1 | CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725445-B2 | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6933295-B2 | Substituted isoindoles and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| EP-1497269-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | Bayer HealthCare AG (DE) | 2005-01-19 | — | — | EP | disclosed |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2003097612-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | F2, SERPINC1, F11 | AAK1 874/4885KDM4A 3754/4885EPAS1 2837/4885 |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | AAK1 4068/4885KDM4A 2897/4885EPAS1 2020/4885 |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | AAK1 3609/4885KDM4A 1534/4885EPAS1 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.